RAC 2.92% $1.94 race oncology ltd

Ann: Expanded Heart Protection Discovery for Zantrene, page-354

  1. 8,407 Posts.
    lightbulb Created with Sketch. 1383
    Wild speculation with no evidence: RAC is currently doing a Zantrene cardioprotection trial with lenvatinib, cabozantinib and pazopanib.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.